Clinical Genomics Market By Test Type, Software, Method and End User - Global Opportunity Analysis and Industry Forecast to 2023

"Clinical Genomics Market By Test Type (Diagnostic, Genetic, Newborn Screening, Prenatal, Carrier Screening), Software, Method (Molecular, Chromosomal, Biochemical Tests), End User (Hospitals & Clinics) - Global Opportunity Analysis and Industry Forecast to 2023"

Global clinical genomics market is expected to reach USD 879.0 million by 2023, at a CAGR of 17.1% during the forecast period of 2018 to 2023.

With the comprehensive secondary and primary research on clinical genomics tests and software and an in-depth analysis of the market scenario, the report carries out an impact analysis of the key industry drivers, restraints, opportunities, challenges, and trends in the global market. The global clinical genomics market is mainly driven by growing significance of early disease detection and prevention, rising insistence for precision medicine, increasing application of genetic testing in oncology, and favourable reimbursement scenario related to genetic testing. However, high cost and social and ethical implications of genetic testing hinder the growth of clinical genomics market to some extent.

Market Segmentation

The global clinical genomics market is mainly segmented by test type (diagnostic testing, genetic testing, newborn screening, prenatal testing, preimplantation testing, carrier screening and other tests), software, method (molecular tests, chromosomal tests, biochemical tests), end user (hospitals & clinics, government laboratories & research centers, academics and research institutes and other end users), and geography (North America, Europe, Asia-Pacific, and Rest of World).

Geographic Overview

Geographically, the global clinical genomics market is segmented into four major regions, namely North America, Europe, Asia-Pacific, and Rest of World. North America accounted for the major share in the global clinical genomics market in 2017, followed by Europe, and Asia-Pacific. The major share of the North American region is mainly attributed to the public awareness regarding genetic testing, high burden of inherited and rare disorders, increasing R&D expenditure, and various government initiatives. On the other hand, Asia-Pacific region is projected to grow at the fastest CAGR during the forecast period, mainly due to increasing population, rising rate of diseases, and various government initiatives for the genomic research in order to understand the complex biological process and genetic mutation present in life-threatening diseases.

The geographical analysis provides detailed insights on the key trends of the industry in the listed regions, identifying the demographic & economic impact, government & private investments, market opportunities and forecast, and regulatory scenario. The geographical analysis section also comments on the key market players shaping the growth of the industry in the respective regions, market size, and forecast for clinical genomics market till 2023.

Key players

The report includes the competitive landscape based on extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past 4 years (2014-2018). The study has also incorporated the detailed profiles of 25 top market players, including detailed financial performance, strategic focus, business overviews, and product offerings of each player. The key players in the global clinical genomics market are Quest Diagnostics Incorporated (U.S.), Eurofins Scientific SE (Luxembourg), Illumina, Inc. (U.S.), PerkinElmer, Inc. (U.S.), NeoGenomics Inc. (U.S.), Foundation Medicine, Inc. (U.S.), Rosetta Genomics Ltd. (Israel), Invitae Corporation (U.S.), Myriad Genetics, Inc. (U.S.), Natera, Inc. (U.S.), Genomic Health, Inc. (U.S.), OPKO Health, Inc. (U.S.), Centogene AG (Germany), Clinical Genomics Pty Ltd. (Australia), 23andMe, Inc. (U.S.), Iverson Genetic Diagnostics, Inc. (U.S.), Veritas Genetics (U.S.), Gene by Gene, Ltd. (U.S.), GenomeDx Biosciences, Inc. (Canada), MedGenome (India), Strand Life Sciences Pvt. Ltd. (India), Beijing Genomics Institute (BGI) (China), Retrogen, Inc. (U.S.), Personalis, Inc. (U.S.), and PathGroup (U.S.).

Scope of the Report:

Market by Test Type:

• Diagnostic Testing
• Genetic Testing
• Newborn Screening
• Preimplantation Testing
• Prenatal Testing
• Carrier Testing
• Other Tests

Market by Method:

• Molecular Tests
• Chromosomal Tests
• Biochemical Tests

Market by End User:

• Hospitals & Clinics
• Government Laboratories & Research Centres
• Academics and Research Institutes
• Other End Users

Market by Geography:

• North America
• U.S.
• Canada
• Europe
• Asia-Pacific
• Rest of World

Key questions answered in the report:

• Which are the high growth market segments in terms of test type, method, end user, and regions/countries?
• What is the historical market for clinical genomics across the globe?
• What are the market forecasts and estimates from the period 2016-2023?
• What are the major drivers, restrains, opportunities, challenges and trends in the global clinical genomics market?
• Who are the major players in the global clinical genomics market and what share of the market do they hold?
• Who are the major players in various regions and what share of the market do they hold?
• What are the competitive landscapes and who are the market leaders by sub-region in the global clinical genomics market?
• What are the recent developments in the global clinical genomics market?
• What are the different strategies adopted by the major players in the global clinical genomics market?
• What are the geographical trends and high growth regions/countries?
• What are the local emerging players in the global clinical genomics market and how do they compete with the global players?